Type Whole antibody Target CD221 CAS Number 934235-44-6 | Source Human ATC code none ChemSpider none | |
Robatumumab (proposed INN), also known as SCH 717454 and MK-7454 is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor.
Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete. Merck has since discontinued development.
References
Robatumumab Wikipedia(Text) CC BY-SA